U.S. Therapeutic Monoclonal Antibodies Markets

Frost & Sullivan
May 25, 2005
SKU: MC1118515
License type:
Table of Contents Related Reports
Countries covered: United States

U.S. Therapeutic Monoclonal Antibodies Markets

 

Dearth of Reliable Conventional Therapies for Serious/Long-term Illnesses Boosts Markets for Therapeutic mAbs

The shortage of reliable conventional therapies for critical illnesses is propelling demand for monoclonal antibodies (mAbs), which work closely with the body’s natural biomedical systems. Estimates indicate that more than two-thirds of therapeutic mAbs are used for transplant rejection, cancer, and autoimmune and infectious diseases. Sales in the billion dollar range and growing investments in mAb development, underline the clinical credibility of the therapy for serious long-term conditions such as non-hodgkin’s disease, psoriasis, allergic asthma, rheumatoid arthritis, and Crohn’s disease. To increase awareness on the benefits of mAbs, it is necessary to allot a large budget, while also implementing well designed communication strategies.

This Frost & Sullivan research service provides an overview of and an outlook for the therapeutic mAb market in United States, detailing revenue forecasts by region and segments as well as providing market share analyses. It looks into the major market sectors for therapeutic mAbs such as oncology, auto-immune and inflammatory disorders, cardiovascular disorders, organ transplants, and infectious diseases. This information is valuable to both large and small market participants seeking to position themselves for maximum return on investment.

High Specificity mAbs Provides Attractive Therapeutic Solutions

mAbs, particularly the human type, have a high binding capacity and specificity that make them suitable for targeted attacks on tumor cells, infectious agents, infected cells, and other human biomaterials related to diseases. It can target any antigen or molecule in the human body. "Unlike the traditional drugs, mAbs can prevent the disease-causing target cells from spreading without damaging the healthy cells in the adjacent tissues," points out the analyst of the research. "They attack specific antigens (within cells, tissues and organs) and do not have off-target effects, thus eliminating side-effects. "Due to this characteristic, mAbs offer high commercial viability and are successfully used in clinical applications.

Broadening Indication Range of Therapeutic mAbs Attract New Patient Groups

With the initial approval being rather cautious, mAbs are often restricted to a single indication comprising smaller patient population. However, companies are extending their indications’ domain within the same disease area, eventually covering different sets of patients. "Enterprises are increasingly conducting research on pipeline products to develop successful multi-target indications, in almost the same amount of time earlier consumed to develop a single product indication," notes the analyst.

To enhance this product development, big pharmaceutical companies are developing alliances with smaller biotech companies in mAb research for specific products and technologies. These alliances can balance the small biotech companies’ capabilities in mAb generation and optimization, along with their process technology and early clinical skills, with the superior drug development capabilities and domestic and global reach of the big pharmaceutical companies.


More United States Antibody Technologies Reports

Strategic Analysis of the U.S. Research Antibodies Market by Frost & Sullivan
This research service evaluates the U.S. research antibodies market during the 2009 to 2016 time period. The research antibodies market includes all antibodies sold for ...

Freedonia Focus on Biologicals by Freedonia Focus
This report discusses US biologicals demand for the years 2004 and 2009, with forecasts for 2014. Topics covered include market size, product and ...

U.S. Biotechnology - Therapeutic Monoclonal Antibodies Market by Frost & Sullivan
This Frost & Sullivan research service titled U.S. Biotechnology - Therapeutic Monoclonal Antibodies Market provides an overview of therapeutic monoclonal antibodies and provides market forecasts, ...

Medical Materials Industry Review by BCC Research
Healthcare was one he better performing industries in 2001 with 13% of the nation’s economic output. The government expects that to continue, with the market ...

The U.S. Market and Developments Associated with Psoriasis by Kalorama Information
Psoriasis has long been a dermatological problem that affects millions of people in the US. Current therapeutic approaches such as lubricants, keratolytic agents and topical ...

See all reports like this >>

More United States Reports

e-Discovery Software Publishing in the US - Industry Market Research Report by IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...

D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country Report: The United States of America by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Country Report United States January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Coal - US - a snapshot (2010) by Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...

See all reports like this >>

 

Share this report


Other tasks

 
 

Research Assistance

Ask a question
 

Related Markets


Antibody Technologies Reports

 
 

Free Alert Me service

Receive bi-weekly email alerts on new market research

Sign Up Today!